ES2900593T3 - Composiciones que comprenden 15-HEPE y su uso para tratar o prevenir la fibrosis pulmonar idiopática - Google Patents

Composiciones que comprenden 15-HEPE y su uso para tratar o prevenir la fibrosis pulmonar idiopática Download PDF

Info

Publication number
ES2900593T3
ES2900593T3 ES15865150T ES15865150T ES2900593T3 ES 2900593 T3 ES2900593 T3 ES 2900593T3 ES 15865150 T ES15865150 T ES 15865150T ES 15865150 T ES15865150 T ES 15865150T ES 2900593 T3 ES2900593 T3 ES 2900593T3
Authority
ES
Spain
Prior art keywords
hepe
agent
approximately
composition
fibrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15865150T
Other languages
English (en)
Spanish (es)
Inventor
Jonathan Rowe
Kevin Duffy
John Climax
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Afimmune Ltd
Original Assignee
Afimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Afimmune Ltd filed Critical Afimmune Ltd
Application granted granted Critical
Publication of ES2900593T3 publication Critical patent/ES2900593T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES15865150T 2014-12-02 2015-12-02 Composiciones que comprenden 15-HEPE y su uso para tratar o prevenir la fibrosis pulmonar idiopática Active ES2900593T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462086535P 2014-12-02 2014-12-02
PCT/US2015/063488 WO2016090030A1 (en) 2014-12-02 2015-12-02 Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same

Publications (1)

Publication Number Publication Date
ES2900593T3 true ES2900593T3 (es) 2022-03-17

Family

ID=56092410

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15865150T Active ES2900593T3 (es) 2014-12-02 2015-12-02 Composiciones que comprenden 15-HEPE y su uso para tratar o prevenir la fibrosis pulmonar idiopática

Country Status (17)

Country Link
US (1) US10363235B2 (OSRAM)
EP (2) EP3988101A1 (OSRAM)
JP (2) JP6986445B2 (OSRAM)
KR (1) KR20170102879A (OSRAM)
CN (2) CN112245419A (OSRAM)
AU (2) AU2015358512B2 (OSRAM)
BR (1) BR112017011685A2 (OSRAM)
CA (1) CA2968980A1 (OSRAM)
ES (1) ES2900593T3 (OSRAM)
IL (2) IL252431B (OSRAM)
MA (1) MA41120A (OSRAM)
MX (2) MX382116B (OSRAM)
PH (1) PH12017501022B1 (OSRAM)
RU (2) RU2721555C2 (OSRAM)
SG (2) SG10202010594WA (OSRAM)
WO (1) WO2016090030A1 (OSRAM)
ZA (2) ZA201704463B (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
JP2016538288A (ja) 2013-11-15 2016-12-08 ディグニティ サイエンシス リミテッド 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩
CA2935986A1 (en) * 2014-01-10 2015-07-16 Mehar Manku Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
HK1247136A1 (zh) * 2015-01-16 2018-09-21 Afimmune Limited 包含15-hepe的组合物和其使用方法
HK1250345A1 (zh) 2015-05-13 2018-12-14 Afimmune Limited 包含15-氧代-epa或15-氧代-dgla的组合物及其制备和使用方法
BR122023026625A2 (pt) 2015-12-18 2024-01-16 Afimmune Limited Uso do ácido 15-hidroxieicosapentaenoico ou derivados farmaceuticamente aceitáveis do mesmo
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180671B1 (en) * 1998-03-10 2001-01-30 Beth Israel Deaconess Medical Center, Inc. Methods for treating disorders in which docosahexaenoic acid (DHA) levels are affected
JP2000191525A (ja) 1998-12-25 2000-07-11 Nof Corp 皮膚外用剤組成物
WO2001049282A2 (en) * 2000-01-06 2001-07-12 Martek Biosciences Corporation Therapeutic preparations of highly unsaturated fatty acids
ATE344226T1 (de) 2000-02-16 2006-11-15 Brigham & Womens Hospital Aspirin-ausgelöste lipidmediatoren
JP2005179211A (ja) 2003-12-17 2005-07-07 Idemitsu Kosan Co Ltd 皮膚外用剤組成物
GB2409644B (en) 2003-12-31 2005-12-21 Igennus Ltd Formulation comprising eicosapentaenoic acid or an ester thereof and a triterpene or an ester thereof
US20050239889A1 (en) 2004-04-26 2005-10-27 Jean Gosselin In vivo release of endogenous anti-microbial mediators by leukotriene B4 (LTB4) administration
ES2527438T3 (es) * 2006-08-08 2015-01-26 Metabolon, Inc. Marcadores de la hepatopatía grasa no alcohólica (NAFLD) y de la esteatohepatitis no alcohólica (NASH) y métodos de uso de los mismos
US8042070B2 (en) * 2007-10-23 2011-10-18 International Business Machines Corporation Methods and system for analysis and management of parametric yield
GB0802116D0 (en) * 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
WO2009154230A1 (ja) 2008-06-17 2009-12-23 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
WO2010120880A1 (en) * 2009-04-14 2010-10-21 Vertex Pharmaceuticals Incorporated Treatment of liver diseases with a caspase inhibitor
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US10154977B2 (en) * 2011-03-25 2018-12-18 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
US20120264824A1 (en) * 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US8658787B2 (en) * 2011-09-16 2014-02-25 Galectin Therapeutics Inc. Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
US8936803B2 (en) 2011-10-19 2015-01-20 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and/or 15-HETrE and methods of use thereof
CA2856715A1 (en) 2011-11-29 2013-06-06 Dignity Sciences Limited Compositions comprising 20-carbon fatty acids and methods of making and using same
CA2859573A1 (en) * 2011-12-16 2013-06-20 Tarix Pharmaceuticals Ltd. Angiotensins for treatment of fibrosis
US20120264705A1 (en) 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
JP6370775B2 (ja) 2012-05-10 2018-08-08 ソルテックス エヌエー エルエルシー 天然の特異的炎症収束性メディエータおよびその前駆物質を含有する、抗炎症活性を有する油
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
TWI742541B (zh) * 2013-03-15 2021-10-11 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
BR122023026625A2 (pt) 2015-12-18 2024-01-16 Afimmune Limited Uso do ácido 15-hidroxieicosapentaenoico ou derivados farmaceuticamente aceitáveis do mesmo

Also Published As

Publication number Publication date
MA41120A (fr) 2017-10-10
ZA201704463B (en) 2018-11-28
BR112017011685A2 (pt) 2018-01-02
KR20170102879A (ko) 2017-09-12
US10363235B2 (en) 2019-07-30
SG10202010594WA (en) 2020-12-30
MX2017007000A (es) 2017-12-07
IL252431B (en) 2021-12-01
AU2015358512A1 (en) 2017-07-20
PH12017501022A1 (en) 2017-11-27
JP6986445B2 (ja) 2021-12-22
IL252431A0 (en) 2017-07-31
RU2020115523A (ru) 2021-01-27
ZA201804380B (en) 2021-03-31
EP3226873A1 (en) 2017-10-11
WO2016090030A1 (en) 2016-06-09
SG11201704495VA (en) 2017-06-29
CN112245419A (zh) 2021-01-22
CA2968980A1 (en) 2016-06-09
EP3988101A1 (en) 2022-04-27
HK1245101A1 (zh) 2018-08-24
MX2021005080A (es) 2021-06-15
AU2021203189A1 (en) 2021-06-10
US20160184252A1 (en) 2016-06-30
EP3226873B1 (en) 2021-10-27
MX382116B (es) 2025-03-13
JP2022031813A (ja) 2022-02-22
AU2015358512B2 (en) 2021-02-18
EP3226873A4 (en) 2018-08-08
CN107206008A (zh) 2017-09-26
RU2721555C2 (ru) 2020-05-20
JP2017536380A (ja) 2017-12-07
PH12017501022B1 (en) 2022-02-16
RU2017122758A3 (OSRAM) 2019-06-13
IL287983A (en) 2022-01-01
RU2017122758A (ru) 2019-01-09

Similar Documents

Publication Publication Date Title
ES2900593T3 (es) Composiciones que comprenden 15-HEPE y su uso para tratar o prevenir la fibrosis pulmonar idiopática
ES2759448T3 (es) Composiciones que comprenden 15-HEPE y métodos de uso de las mismas
ES2948444T3 (es) Composiciones que comprenden 15-HEPE
ES2846003T3 (es) Procedimientos para tratar afecciones pruriginosas mediadas por receptores de histamina H-4
JP7229285B2 (ja) １５－オキソ－ｅｐａまたは１５－オキソ－ｄｇｌａを含む組成物、ならびにその作製及び使用方法
JP2013507454A5 (OSRAM)
US12390470B2 (en) 1-methylxanthine-based bioactive composition and method of use thereof
ES2851525T3 (es) Composiciones que comprenden 15(S)-HEPE para su uso en la sensibilización de las células cancerosas a la radioterapia
HK1245101B (en) Compositions comprising 15-hepe and its use for treating or preventing idiopathic pulomonary fibrosis
JP2016534024A (ja) 熱産生を増大させることができる組成物およびその使用
WO2017085148A1 (en) Composition comprising vitamin k2 or a provitamin thereof for use in the transformation of white adipose tissue to brown adipose tissue, especially to beige adipose tissue